Auro Laboratories
Market Cap
₹330.3m
Last Updated
2019/10/14 12:31 UTC
Data Sources
Company Financials
Executive Summary
Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generics in India.
Snowflake
Fundamentals
Excellent balance sheet with solid track record.
Share Price & News
How has Auro Laboratories's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-4.5%
530233
-2.0%
IN Pharmaceuticals
0.5%
IN Market
1 Year Return
-28.6%
530233
-20.5%
IN Pharmaceuticals
0.9%
IN Market
Return vs Industry: 530233 underperformed the Indian Pharmaceuticals industry which returned -20.5% over the past year.
Return vs Market: 530233 underperformed the Indian Market which returned 0.9% over the past year.
Share holder returns
| 530233 | Industry | Market | |
|---|---|---|---|
| 7 Day | -4.5% | -2.0% | 0.5% |
| 30 Day | 3.5% | -7.9% | 1.0% |
| 90 Day | -4.6% | -7.3% | -3.2% |
| 1 Year | -28.6%-28.6% | -19.7%-20.5% | 2.8%0.9% |
| 3 Year | 30.4%30.4% | -27.8%-29.3% | 20.3%14.3% |
| 5 Year | 633.3%633.3% | -11.5%-14.1% | 43.1%29.8% |
Price Volatility Vs. Market
How volatile is Auro Laboratories's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Auro Laboratories undervalued based on future cash flows and its price relative to the stock market?
>50%
Discount to future cash flow value
Intrinsic Value Based on Future Cash Flows
Undervalued: 530233 (₹52.8) is trading below our estimate of fair value (₹133.3)
Significantly Undervalued: 530233 is trading below fair value by more than 20%.
Price Based on Earnings
PE vs Industry: 530233 is good value based on its PE Ratio (6.8x) compared to the Pharmaceuticals industry average (15.7x).
PE vs Market: 530233 is good value based on its PE Ratio (6.8x) compared to the Indian market (13.1x).
Price Based on Expected Growth
Low PEG Ratio: Insufficient data to calculate 530233's PEG Ratio to determine if it is good value.
Price Based on Value of Assets
PB vs Industry: 530233 is overvalued based on its PB Ratio (1.9x) compared to the IN Pharmaceuticals industry average (1.5x).
Next Steps
Future Growth
How is Auro Laboratories expected to perform in the next 1 to 3 years based on estimates from 0 analysts?
-0.08%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Earnings vs Savings Rate: 530233's earnings are forecast to decline over the next 3 years (-0.08% per year).
Earnings vs Market: 530233's earnings are forecast to decline over the next 3 years (-0.08% per year).
High Growth Earnings: 530233's earnings are forecast to decline over the next 3 years.
Revenue vs Market: Insufficient data to determine if 530233's revenue is forecast to grow faster than the Indian market.
High Growth Revenue: Insufficient data to determine if 530233's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Estimates
Future Return on Equity
High Future ROE: Insufficient data to determine if 530233's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Auro Laboratories performed over the past 5 years?
44.6%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: 530233's earnings have grown significantly by 44.6% per year over the past 5 years.
Accelerating Growth: 530233's earnings growth over the past year (30.8%) is below its 5-year average (44.6% per year).
Earnings vs Industry: 530233 earnings growth over the past year (30.8%) exceeded the Pharmaceuticals industry 16.4%.
Return on Equity
High ROE: 530233's Return on Equity (28%) is considered high.
Return on Assets
ROA vs Industry: 530233 has a higher Return on Assets than the Pharmaceuticals industry average last year.
Return on Capital Employed
ROCE Improving: 530233 has significantly improved its Return on Capital Employed over the past 3 years.
Next Steps
Financial Health
How is Auro Laboratories's financial position?
Financial Position Analysis
Short Term Liabilities: 530233's short term assets (₹187.1M) exceeds its short term liabilities (₹64.6M)
Long Term Liabilities: 530233's short term assets (187.1M) exceeds its long term liabilities (95.9M)
Debt to Equity History and Analysis
Debt Level: 530233's debt to equity ratio (46.5%) is considered high
Reducing Debt: 530233's debt to equity ratio has reduced from 214.6% to 46.5% over the past 5 years.
Debt Coverage: 530233's debt is well covered by operating cash flow (84.9%).
Interest Coverage: 530233's interest payments on its debt are well covered by EBIT (9.6x coverage).
Balance Sheet
Inventory Level: 530233 has a high level of physical assets or inventory.
Debt Coverage by Assets: 530233's debt is covered by short term assets (assets are 2.312060x debt).
Next Steps
Dividend
What is Auro Laboratories's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Dividend Yield and Payments Analysis
Notable Dividend: Unable to evaluate 530233's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 530233's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if 530233's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 530233's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 530233's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.
Next Steps
Management
What is the CEO of Auro Laboratories's salary, the management and board of directors tenure and is there insider trading?
₹6m
CEO Compensation
CEO
Sharat Deorah (69yo)
0yrs
Tenure
₹6,000,000
Compensation
Mr. Sharat Sahadeolal Deorah, B.Com. serves as the Managing Director and Chairman of the Board at Auro Laboratories Limited.
CEO Compensation Analysis
Compensation vs. Market: Sharat's total compensation ($USD84.59K) is about average for companies of similar size in the Indian market ($USD25.38K).
Compensation vs Earnings: Sharat's compensation has increased by more than 20% in the past year.
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Management Team
Sharat Deorah (69yo)
Chairman & MD
- Tenure: 0yrs
- Compensation: ₹6.00m
Siddhartha Deorah (41yo)
Whole Time Director
- Tenure: 0yrs
- Compensation: ₹6.00m
Amit Shah
Chief Financial Officer
- Tenure: 0yrs
- Compensation: ₹1.04m
Shanu Nag
Company Secretary
- Tenure: 0yrs
- Compensation: ₹180.10k
Board Members
Sharat Deorah (69yo)
Chairman & MD
- Tenure: 0yrs
- Compensation: ₹6.00m
Govardhan Agarwal (70yo)
Non-Executive Independent Director
- Tenure: 0yrs
- Compensation: ₹12.50k
Siddhartha Deorah (41yo)
Whole Time Director
- Tenure: 0yrs
- Compensation: ₹6.00m
Kailash Bubna (65yo)
Non-Executive Independent Director
- Tenure: 10.3yrs
- Compensation: ₹12.50k
Kavita Sharma
Woman Director
- Tenure: 5.6yrs
- Compensation: ₹12.50k
Company Information
Auro Laboratories Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Auro Laboratories Limited
- Ticker: 530233
- Exchange: BSE
- Founded: 1989
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹330.323m
- Shares outstanding: 6.23m
- Website: https://www.aurolabs.com
Number of Employees
Location
- Auro Laboratories Limited
- 314, T.V. Industrial Estate
- 3rd Floor
- Mumbai
- Maharashtra
- 400030
- India
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 530233 | BSE (Mumbai Stock Exchange) | Yes | Equity Shares | IN | INR | Oct 2004 |
Biography
Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generics in India. It offers APIs for various drugs, such as antihistamine, muscle relaxant, di ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/14 12:31 |
| End of Day Share Price | 2019/10/14 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.